Loading stock data…
Palvella Therapeutics (PVLA)
$151.29+3.08 (+2.08%)
Market OpenUpdated 3:16 PM EDT
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Palvella Therapeutics, Inc. in the Healthcare sector is trading at $151.29 with a market capitalization of $1.6B. Wall Street consensus targets $229.60 (15 analysts), implying a +51.8% move over the next 12 months. The stock is currently near its 52-week high of $151.36, remaining 51.2% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +51.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$14.86M↓ | -$11.30M↓ | -$10.18M↓ | -$9.25M↓ | -$7.87M |
| Net Income | -$15.77M↓ | -$12.71M↓ | -$11.35M↓ | -$9.47M↓ | -$8.19M |
Peer Comparison
JNJUNHPFE
Fundamentals
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a n...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.22%
Volume
Today's trading volume
246,219
Recent News
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
Focused on rare skin disease therapies, this clinical-stage biotech just reported a notable insider sale amid a year of sharp stock gains.
Palvella Shares Advance After FDA Grants Rolling Review for Rare Disease Therapy
Palvella Therapeutics Inc (NASDAQ:PVLA) shares gained 5% in premarket trading on Monday after the company announced that the U. S.
Palvella Therapeutics (PVLA) Stock Valuation Check After Strong Recent Momentum
Palvella Therapeutics stock snapshot Palvella Therapeutics (PVLA) has been drawing attention after recent trading, with the stock last closing at $116.51 and a market value of about $1.56b, prompting closer scrutiny from rare disease focused investors. See our latest analysis for Palvella Therapeutics. The recent 7.08% 1 day share price return and 10.70% 7 day share price return come after a year where total shareholder return is very large. This suggests momentum is building despite a softer...
Palvella’s QTORIN Trial Data Reframes Venous Malformation Outlook And Valuation
Palvella Therapeutics (NasdaqGM:PVLA) presented new Phase 2 TOIVA data for QTORIN rapamycin in cutaneous venous malformations at a major dermatology conference. The trial showed statistically significant improvements in bleeding outcomes for patients. Patient interviews highlighted the wide quality of life impact of cutaneous venous malformations and informed the assessment of QTORIN rapamycin's clinical benefit. For investors tracking Palvella Therapeutics, the new QTORIN rapamycin data...
Palvella Therapeutics Q1 Earnings Call Highlights
Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin in Microcystic Lymphatic Malformations, after reporting what executives described as positive Phase 3 results and outlining an expanded commercial plan suppor